Cardioprotection From Cardiotoxicity: The Quest for the Holy Grail Goes On

Affiliations

¹ Heart Failure Center and Cardio-Oncology Center, Harrington Heart & Vascular Institute, University Hospitals Health System, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.

Editorial

Guilherme H Oliveira. JACC CardioOncol. 2019.

. 2019 Sep 24;1(1):66-67.

doi: 10.1016/j.jaccao.2019.08.013. eCollection 2019 Sep.

¹ Heart Failure Center and Cardio-Oncology Center, Harrington Heart & Vascular Institute, University Hospitals Health System, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.

No abstract available

Keywords: anthracyclines; cardioprotection; cardiotoxicity; chemotherapy; meta-analysis; trastuzumab.

Figures

Efficacy of Neurohormonal Therapies in Preventing Cardiotoxicity in Patients with Cancer Undergoing Chemotherapy.
Vaduganathan M, Hirji SA, Qamar A, Bajaj N, Gupta A, Zaha V, Chandra A, Haykowsky M, Ky B, Moslehi J, Nohria A, Butler J, Pandey A. Vaduganathan M, et al. JACC CardioOncol. 2019 Sep;1(1):54-65. doi: 10.1016/j.jaccao.2019.08.006. Epub 2019 Sep 24. JACC CardioOncol. 2019. PMID: 33083790 Free PMC article.

1. Lefrak E.A., Pitha J., Rosenheim S. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer. 1973;32:302–314. - PubMed
1. Hudis C., Seidman A., Paton V. Characterization of cardiac dysfunction observed in the Herceptin (trastuzumab) clinical trials [abstract 24]. 21st Annual San Antonio Breast Cancer Symposium. December 12–15, 1998, San Antonio, Texas. Breast Cancer Res Treat. 1998;50:232.
1. Zhang S., Liu X., Bawa-Khalfe T. Identification of the molecular basis of doxorubicininduced cardiotoxicity. Nat Med. 2012;18:1639–1642. - PubMed
1. Vejpongsa P., Yeh E.T. Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. J Am Coll Cardiol. 2014;64:938–945. - PubMed
1. Force T., Krause D.S., Van Etten R.A. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer. 2007;7:332–344. - PubMed